Pfizer Q1 revenue $14.9B (-20% YoY); adj. EPS $0.82; raises FY adj. EPS guidance

PFIZER INC

2024-Q1 EPS reported $0.55 revenue$14,879,000,000

Q1 revenue $14.9B, operational decline 19% YoY; ex-COVID products grew 11% operationally.
Reported diluted EPS $0.55; adjusted diluted EPS $0.82 (includes $0.11 favorable Paxlovid return adjustment).
Full-year 2024 revenue guidance reaffirmed at $58.5-$61.5B; adjusted EPS guidance raised to $2.15-$2.35.
Cost realignment program on track to deliver at least $4 billion net cost savings by end of 2024.
Notable approvals: Beqvez (hemophilia B) FDA approval, Prevenar 20 (pediatrics) EU approval, Tivdak full FDA approval.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PFIZER INC reported first quarter of 2024 results: revenue $14,879 million, net income $3,115 million, EPS $0.55. Guidance raised.

Period: first quarter of 2024
Revenue: $14,879 million
Net income: $3,115 million
EPS: $0.55
Guidance: raised
Result: reported results

Exact text from the filing

First-Quarter 2024 Results ▪ Solid First-Quarter Results Reflect Continued Growth of Key Products and Progress in Executing 2024 Priorities ▪ First-Quarter 2024 Revenues of $14.9 Billion – Expected Decline in Comirnaty (1) and Paxlovid Revenues Drove a Year-Over-Year Operational Decrease in Revenues of 19% – Excluding Contributions from Comirnaty (1) and

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

PFIZER INC filing history →

Source: SEC EDGAR

accession 0000078003-24-000103

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.